Exploring Options for First- and Second-Line Therapies in cSCCDecember 31st 2020
The plan of treatment for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was the topic of discussion among Dan Paul Zandberg, MD, and other clinicians in attendance during a Targeted Oncology Case-Based Peer Perspectives event.
Expert Expands on Treatment Choices in Patients With Genomic Aberrations in CLLDecember 30th 2020
During a Targeted Oncology Case-Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed therapeutic options for a 71-year-old patients with chronic lymphocytic leukemia and a genomic aberration.
Deciding on an Agent for Prostate Cancer Involves Careful Consideration of Prior TherapyDecember 28th 2020
Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.
Discussing Therapies Currently Available in High-Grade Epithelial Ovarian CancerDecember 25th 2020
During a Targeted Oncology Case Based Peer Perspectives event, John K. Chan, MD, reviewed the case of a 49-year-old African American woman with high-grade epithelial ovarian cancer.
New Evidence Supports Targeted Therapies in Early-Stage NSCLC With EGFR MutationsDecember 16th 2020
During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.
Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCLDecember 1st 2020
During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.